TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06622200

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Intervention
Description: In the present research, the standardized, theory based MBI was introduced to the experimental group (Smith, 2005). This 30-minute protocol involves a series of activities, including paying attention to and being aware of breath, body sensations, thoughts, and sounds without judgment. This protocol is a widely recognized and utilized method due to its simplicity and accessibility, making it an ideal choice for this study.~Participants in the experimental group completed three weekly sessions of MBI for five weeks during their hemodialysis treatments (Alhawatmeh et al., 2022). Participants were provided with audio recordings of the MBI protocol, which they could practice during hemodialysis sessions. These recordings were delivered via email and WhatsApp, depending on their preference. This audio recording was developed based on the Smith's protocol by a certified study researcher who had a higher degree in nursing and extensive experience in practicing and delivering MBIs.
Study: NCT06618209

Intervention type: DIAGNOSTIC_TEST
Intervention: physical and chemical methods
Description: Salivary flow rate, pH

Intervention type: DIAGNOSTIC_TEST
Intervention: physical and chemical methods
Description: Salivary flow rate, pH

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical methods
Description: Total oxidant and antioxidant capacities, Lactoperoxidase, Oxidative Stress Index, Glutathione, Superoxide Dismutase

Intervention type: DIAGNOSTIC_TEST
Intervention: biochemical methods
Description: Total oxidant and antioxidant capacities, Lactoperoxidase, Oxidative Stress Index, Glutathione, Superoxide Dismutase

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Findings
Description: DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries. DDE Index: Developmental Defects of Enamel index.GI (Gingival Index): Assesses the severity of gingivitis based on inflammation.PI (Plaque Index): Assesses the severity of plaque based on inflammation. basic erosive wear examination: measures dental erosion

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral Findings
Description: DMFT/dft Index: Measures decayed, missing, and filled teeth. ICDAS II: International Caries Detection and Assessment System, used for detecting and assessing dental caries. DDE Index: Developmental Defects of Enamel index.GI (Gingival Index): Assesses the severity of gingivitis based on inflammation.PI (Plaque Index): Assesses the severity of plaque based on inflammation. basic erosive wear examination: measures dental erosion

Intervention type: DIAGNOSTIC_TEST
Intervention: Pediatric Oral Health Quality of Life
Description: The Pediatric Oral Health Quality of Life (POQL) Scale is a tool used to assess the impact of oral health conditions on the overall quality of life in children.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pediatric Oral Health Quality of Life
Description: The Pediatric Oral Health Quality of Life (POQL) Scale is a tool used to assess the impact of oral health conditions on the overall quality of life in children.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pediatric Oral Health Quality of Life
Description: The Pediatric Oral Health Quality of Life (POQL) Scale is a tool used to assess the impact of oral health conditions on the overall quality of life in children.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pediatric Oral Health Quality of Life
Description: The Pediatric Oral Health Quality of Life (POQL) Scale is a tool used to assess the impact of oral health conditions on the overall quality of life in children.
Study: NCT06621628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching, strengthening exercises and active exercises
Description: Bioptron light therapy device, resisted exercises and stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching, strengthening exercises and active exercises
Description: Bioptron light therapy device, resisted exercises and stretching exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stretching, strengthening exercises and active exercises
Description: Bioptron light therapy device, resisted exercises and stretching exercises
Study: NCT06158815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive neuromuscular facilitation exercise
Description: The basic principle of Proprioceptive Neuromuscular Facilitation exercises, which is defined as facilitating the responses of the neuromuscular mechanism by stimulating the proprioceptors, is that the movements in the human body have a rotational and oblique character and that a greater response can be obtained with movement against maximum resistance. It is aimed to achieve improvement in strength and movement ability through hand contacts, visual and verbal stimuli.
Study: NCT06249854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bojungikki-tang(BJIKT)
Description: Bojungikgitang, which is a classical formulation widely used in South Korea, China, and Japan for a long time, has been reported to have following anticancer activities.~1. Protective effect of intestine and hematopoietic organs against radiation damage~2. Improving localized radiotherapy-induced immune deterioration~3. Improving cancer-related fatigue and QOL~4. Reducing radiation or chemotherapy induced side effects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: It is a humanized antibody used in cancer immunotherapy for various types of cancer, including lung cancer. It targets the programmed cell death protein 1 (PD-1) receptor of lymphocytes. It was approved for medical use in the U.S. in 2014.
Study: NCT06619262

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS stands for transcutaneous electrical nerve stimulation. Transcutaneous means across the skin. TENS machines pass a small electrical current across your skin to stimulate the nerves.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS stands for transcutaneous electrical nerve stimulation. Transcutaneous means across the skin. TENS machines pass a small electrical current across your skin to stimulate the nerves.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular and Muscular Electrical Stimulation
Description: Neuromuscular and Muscular Electrical Stimulation (NMES) is a modality that sends electrical impulses to nerves which causes the muscles to contract mimicking the action potential coming from the central nervous system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular and Muscular Electrical Stimulation
Description: Neuromuscular and Muscular Electrical Stimulation (NMES) is a modality that sends electrical impulses to nerves which causes the muscles to contract mimicking the action potential coming from the central nervous system.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise program
Description: Specific exercise program for patients with lower extremity hemiparesis after stroke

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Specific exercise program for patients with lower extremity hemiparesis after stroke

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise program
Description: Specific exercise program for patients with lower extremity hemiparesis after stroke

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Specific exercise program for patients with lower extremity hemiparesis after stroke
Study: NCT04889157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06882961
Description: Participants will be administered active doses, taking 3 tablets twice daily (BID) for 8 weeks except Day 1 (QD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 matching placebo tablets taken twice daily (BID) except Day 1 (QD)
Study: NCT05499260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB03-154
Description: CB03-154 tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily.
Study: NCT06358209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventricular irrigation
Description: Dual-catheter ventricular irrigation, with the lavage catheter placed in the frontal horn of lateral ventricle, and the drainage catheter placed through another burr hole in the ipsilateral occipital horn or in the contralateral ventricle. Lavage is performed twice daily, with each time 500ml of saline over a duration of one hour. Aside from lavage sessions, the lavage is paused, but continuous CSF drainage remains open.
Study: NCT06298474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The BRAIN App
Description: The BRAIN App is digital engagement platform that uses AI to tailor activities to each person's specific interests / background.
Study: NCT04889196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride
Description: Previous studies have recommended that Silver diamine fluoride (SDF) solution would exert a preventive result in managing early childhood caries ECC. However, no well-designed clinical trials have yet been performed to study the effect of SDF on caries prevention. the objective is useful in arresting early childhood caries (ECC)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hall technique
Description: The first report on the Hall Technique published in 2007 by a general dental practitioner from Aberdeen/Scotland, Dr. Norna Hall. Dr. Hall used PMCs to restore carious primary molars rather than using the standard technique, placed them using a simplified method.
Study: NCT04743804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Body weight-based doses of ravulizumab will be administered intravenously as loading dose regimen followed by maintenance dosing every 8 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Study: NCT05883293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cell Free Fat Extract(CEFFE)
Description: The subjects inhaled 2ml of CEFFE each time in a nebulized inhalation method, inhaling every 3 days, for a total of 7 inhalations
Study: NCT06385340

Intervention type: OTHER
Group type: OTHER
Intervention: Lipikar Baume AP+M
Description: • Lipikar Baume AP+M Application of Lipikar Baume AP+M at least twice daily for 4 weeks on one of the two arms according to a randomization scheme
Study: NCT05769868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol Injection [Brevibloc]
Description: Brevibloc® will be administered intravenously by infusion pump following the administration schedule:~Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes.~If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute.~The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg.~The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min).
Study: NCT05157542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Day 1 and 22, 1500mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin bound paclitaxel
Description: Day1 and 22 nanoparticle albumin-bound paclitaxel 260 mg/m2 and carboplatin AUC 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low dose radiation therapy
Description: 10 Gy in 5 fractions, 20 Gy in 10 fractions, 30 Gy in 15 fractions respectively in our three groups from Day1
Study: NCT04378959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine patch
Description: Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine patch
Description: Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo patch
Description: Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: Up to 3 patches will be applied for 12 hours on (e.g. from 8 AM to 8 PM for those whose pain is worse during the day, or from 8 PM to 8 AM for those whose pain is worse at night) and 12 hours off x 4 weeks.
Study: NCT06098872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib tablet
Description: Drug is supplied in 2mg and 0.5 mg tablets
Study: NCT05672407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: 100 mg/mL Tranexamic acid with lidocaine with 1:100,000 epinephrine in 1:1 manner administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lidocaine with 1:100,000 epinephrine mixed with 1:1 Basal Saline Solution (BSS) administered subcutaneously
Study: NCT04888403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab+Nedaplatin+Albumin Paclitaxel
Description: Toripalimab 240mg administered intravenously (IV) on Day 1 of each 21-day cycle for 1 cycles.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel Neoadjuvant radiotherapy after 2W: The radiotherapy dose is 41.4Gy, completed in 23 times, 5 times a week, using intensity-modulated radiotherapy (IMRT) or volume-modulated radiotherapy (VMAT); In the same period, albumin paclitaxel combined with nedaplatin chemotherapy: albumin paclitaxel 60mg/m2 + nedaplatin 25mg/m2, performed once a week, 5 times in total; Simultaneous immunotherapy: 240 mg of Toripalimab (PD-1 antibody), once every 3 weeks, 4 times in total; Received radical resection of esophageal cancer within 7 weeks after radiotherapy and chemotherapy.~Other Names:Toripalimab+Nedaplatin+Albumin Paclitaxel
Study: NCT05176626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Lifestyle Behavioral Therapy
Description: Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Online Lifestyle Behavioral Therapy
Description: Participants will receive access to the WW™ digital application for the duration of their participation. The WW™ digital application can be accessed using a smartphone, tablet or personal computer and includes functions such as food journaling, progress charts, lifestyle coaching , ability to manually enter exercise data or link with a fitness tracking device, incentives for behavior change, recipes, and local restaurant recommendations using GPS. Over the course of 12 clinic visits with an obesity provider, participants will be prescribed a dietary plan based on the WW™ app and will be asked to journal dietary intake.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine Hydrochloride 8 MG
Description: At the randomization visit, participants will be started on 8 mg PO daily of phentermine or placebo, with a recommendation to take the medication in the morning. They will be provided with detailed instructions on how to increase their dose of study drug over the subsequent weeks. After one week, participants will increase to 16 mg daily. After the second week, participants will further increase their dose to 24 mg daily and at the 1-month in-person follow-up, participants who tolerate the 24 mg dose will be maintained on this as the maximum daily dose for a total of 24 months. For participants who do not tolerate an escalation in medication dose due to side effects, adverse events, and/or elevations in blood pressure and/or heart rate, the study clinician may adjust the dose and/or delay dose escalation. Study clinicians will work with participants to achieve and sustain the maximum dose tolerated.
Study: NCT04875390

Intervention type: OTHER
Group type: OTHER
Intervention: Erector spina plane block
Description: After the surgery is completed, intraoperative Erector spina plane block will be performed

Intervention type: OTHER
Group type: OTHER
Intervention: local infiltration
Description: After the surgery is completed, intraoperative local infiltration will be performed
Study: NCT05860725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSA Development
Description: Health sciences students from a regional community college in Appalachian Virginia will be asked to to develop and submit a public service announcement (PSA) and to watch virtual training webinars that support the development of the PSAs. They will also be asked to complete surveys at three time points: before the PSA contest starts, after the PSA contest ends, and upon submitting a PSA.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HPV vaccination focused social marketing campaign
Description: Community members who use a regional health services focused non-profits rideshare buses and/or view their social media pages will be exposed to a 12-week social marketing campaign that uses PSAs developed in Phase 1. Community members will also complete surveys at three time points: before the start of the social marketing campaign, during the social marketing campaign, and after the social marketing campaign.
Study: NCT05099016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Joint Effort
Description: The Joint Effort intervention is available in the form of an iPhone mobile application (running on iOS 13 and 14) in French language. It aims to support young adults in school who have used cannabis in the past month into taking action on their cannabis use.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief normative feedback and standard information
Description: The brief normative feedback is based on the frequency of cannabis use use. Participants will also be offered basic reliable non personalized information on lower-risk cannabis use in the form of official public websites.
Study: NCT06017687

Intervention type: DEVICE
Group type: OTHER
Intervention: OptiBP Study app
Description: Each participant will use OptiBP Study app to measure their blood pressure optically by applying their fingertip to their smartphone camera, and subsequently enter the blood pressure values obtained by measuring it with their own blood pressure cuff.
Study: NCT06525753

Intervention type: OTHER
Intervention: Weaning off Parenteral Nutrition
Description: pediatric intestinal failure patients who have been weaned off parenteral nutrition

Intervention type: OTHER
Intervention: Weaning off Parenteral Nutrition
Description: pediatric intestinal failure patients who have been weaned off parenteral nutrition
Study: NCT05680298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: solution for injection, Subcutaneous injection
Study: NCT05936203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insulin therapy adjustment
Description: Strategies used to manage glucose control during a prolonged aerobic exercise
Study: NCT04593095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NeuroN-QI
Description: SSC session lasting 2-hr during the day 4 times/wk including a 15-min of auditory stimulation with maternal voice and controlled levels of NICU light and noise followed by a 1-hr quiet period where infants will rest in their incubator/crib with olfactory stimulation and where the control of light and noise levels will be continued.
Study: NCT04943302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: To be given by IV at 70mg/m2 on cycle days 1 and 8 for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: To be given by IV at10mg/kg IV on cycle 1 days 1,8,15, and 22; cycle 2-6 days 1,8; and cycle 7-12 days 1